Tirzepatide 5mg

Tirzepatide 5 mg may have a greater effect than strict GLP-1R agonists since it may show synergistic agonistic potential on the GLP-1 and GIP receptors. According to research, tirzepatide may have a higher affinity for GIP-R than GLP-1R. The small intestine naturally produces GIP or glucose-dependent insulinotropic polypeptide. Insulin is released when binding to GIP-R occurs; however, gastrin and acid secretion are inhibited. The brain’s beta cells and neurons contain GLP-1R, and activating it increases insulin synthesis and release, decreasing appetite. Furthermore, through improving bcl-2 gene expression and lowering apoptosis, GLP-1R activation raises beta cell density in the pancreas and ultimately raises insulin levels.(3)

According to research, Tirzepatide may function at GIP-R exactly like GIP does, but at GLP-1R, it seems to prioritize cAMP synthesis over β-arrestin recruitment. Tirzepatide has the potential to be more effective than other synthetic GLP-1R agonists because of its distinct action from endogenous GLP-1, which results in increased GLP-1R activity without increasing the physiological internalization of the receptor. Tirzepatide decreases inflammation in adipose tissue, increases fullness sensations, and may stimulate insulin release.

Moreover, tirzepatide may alter adiponectin levels, raising total amounts of this peptide that burns fat, decreasing the differentiation of fat cells, and raising energy expenditure. Type 2 diabetes, non-alcoholic fatty liver, and atherosclerosis are all linked to low adiponectin levels. (4)